Francisco Partners Iv, L.P. Sells 143,594 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 143,594 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $3.46, for a total transaction of $496,835.24. Following the transaction, the insider directly owned 706,649 shares of the company’s stock, valued at approximately $2,445,005.54. This trade represents a 16.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50.
• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The shares were sold at an average price of $3.44, for a total value of $437,819.12.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Down 3.8%

Shares of NASDAQ:GDRX opened at $3.51 on Friday. The company has a market capitalization of $1.20 billion, a P/E ratio of 87.77, a P/E/G ratio of 1.82 and a beta of 1.60. The stock’s fifty day simple moving average is $3.19 and its 200-day simple moving average is $2.67. GoodRx Holdings, Inc. has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.09 EPS. As a group, equities research analysts forecast that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GDRX has been the topic of a number of analyst reports. Leerink Partners set a $5.00 target price on shares of GoodRx in a research report on Thursday, August 6th. Wells Fargo & Company boosted their price target on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Barclays increased their price target on GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Thursday, August 20th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of GoodRx in a research report on Friday, August 7th. Finally, Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, GoodRx has a consensus rating of “Hold” and an average target price of $4.23.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently bought and sold shares of the stock. Technology Crossover Management X Ltd. acquired a new stake in shares of GoodRx during the 2nd quarter worth $4,762,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in GoodRx during the fourth quarter valued at about $1,585,000. LSV Asset Management increased its stake in GoodRx by 20.0% during the fourth quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after acquiring an additional 471,319 shares during the last quarter. Prescott Group Capital Management L.L.C. purchased a new position in shares of GoodRx in the 4th quarter worth about $4,812,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of GoodRx by 10,242.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after purchasing an additional 1,488,137 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.